Rationale and design of WEBCARE: a randomized, controlled, web-based behavioral intervention trial in cardioverter-defibrillator patients to reduce anxiety and device concerns and enhance quality of life

Susanne S Pedersen, Viola Spek, Dominic A M J Theuns, Marco Alings, Pepijn van der Voort, Luc Jordaens, Pim Cuijpers, Johan Denollet, Krista C van den Broek, Susanne S Pedersen, Viola Spek, Dominic A M J Theuns, Marco Alings, Pepijn van der Voort, Luc Jordaens, Pim Cuijpers, Johan Denollet, Krista C van den Broek

Abstract

Background: The implantable cardioverter defibrillator (ICD) is generally well accepted, but 25-33% of patients experience clinical levels of anxiety, depression, and impaired quality of life (QoL) following implantation. Few trials in ICD patients have investigated whether behavioral intervention may mitigate the development of these adjustment problems. We present the rationale and study design of the WEB-based distress management program for implantable CARdioverter dEfibrillator patients (WEBCARE) trial.

Methods: WEBCARE is a multi-center, multi-disciplinary, randomized, controlled behavioral intervention trial designed to examine the effectiveness of a web-based approach in terms of reducing levels of anxiety and device concerns and enhancing QoL. Consecutive patients hospitalized for the implantation of an ICD will be approached for study participation while in hospital and randomized to the intervention arm (n = 175) versus usual care (n = 175) at baseline (5-10 days post implantation). Patients will complete assessments of patient-centered outcomes at baseline, 14, 26, and 52 weeks after implantation. Patients randomized to the intervention arm will receive a 12-week web-based behavioral intervention starting 2 weeks after implantation. Primary endpoints include (i(i)) patient-centered outcomes (i.e., anxiety, depression, ICD acceptance, QoL); (i(ii)) health care utilization; and (i(iii)) cost-effectiveness. All primary endpoints will be assessed with standardized and validated disease-specific or generic questionnaires. Secondary endpoints include (ii(i)) cortisol awakening response; and (ii(ii)) ventricular arrhythmias.

Discussion: WEBCARE will show whether a behavioral intervention using a web-based approach is feasible and effective in reducing anxiety and ICD concerns and improving QoL in ICD patients.

Trial registration: http://www.ClinicalTrials.gov. Identifier: NCT00895700.

Figures

Figure 1
Figure 1
Schematic representation of the study procedure.

References

    1. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Smith SC Jr, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, Nishimura R, Ornato JP, Page RL, Riegel B, Blanc JJ, Budaj A, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL. American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e385–484. doi: 10.1161/CIRCULATIONAHA.106.178233.
    1. Crespo EM, Kim J, Selzman KA. The use of implantable cardioverter defibrillators for the prevention of sudden cardiac death: a review of the evidence and implications. Am J Med Sci. 2005;329:238–246. doi: 10.1097/00000441-200505000-00005.
    1. Seidl K, Senges J. Worldwide utilization of implantable cardioverter/defibrillators now and in the future. Card Electrophysiol Rev. 2003;7:5–13. doi: 10.1023/A:1023603118860.
    1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics -- 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21–e181. doi: 10.1161/CIRCULATIONAHA.108.191261.
    1. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883. doi: 10.1056/NEJMoa013474.
    1. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150. doi: 10.1056/NEJMoa032423.
    1. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237. doi: 10.1056/NEJMoa043399.
    1. Johansen JB, Pedersen SS, Spindler H, Andersen K, Nielsen JC, Mortensen PT. Symptomatic heart failure is the most important clinical correlate of impaired quality of life, anxiety, and depression in implantable cardioverter-defibrillator patients: a single-centre, cross-sectional study in 610 patients. Europace. 2008;10:545–551. doi: 10.1093/europace/eun073.
    1. Bostwick JM, Sola CL. An updated review of implantable cardioverter/defibrillators, induced anxiety, and quality of life. Psychiatr Clin North Am. 2007;30:677–688. doi: 10.1016/j.psc.2007.07.002.
    1. Matchett M, Sears SF, Hazelton G, Kirian K, Wilson E, Nekkanti R. The implantable cardioverter defibrillator: its history, current psychological impact and future. Expert Rev Med Devices. 2009;6:43–50. doi: 10.1586/17434440.6.1.43.
    1. Broek KC Van den, Nyklicek I, Van der Voort PH, Alings M, Denollet J. Shocks, personality, and anxiety in patients with an implantable defibrillator. Pacing Clin Electrophysiol. 2008;31:850–857. doi: 10.1111/j.1540-8159.2008.01099.x.
    1. Pedersen SS, Theuns DA, Muskens-Heemskerk A, Erdman RA, Jordaens L. Type D personality but not implantable cardioverter-defibrillator indication is associated with impaired health-related quality of life 3 months post-implantation. Europace. 2007;9:675–680. doi: 10.1093/europace/eum041.
    1. Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR, Kutalek SP, Friedman PL, Bubien RS, Page RL, Powell J. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 2002;105:589–594. doi: 10.1161/hc0502.103330.
    1. Sears SF Jr, Conti JB. Quality of life and psychological functioning of ICD patients. Heart. 2002;87:488–493. doi: 10.1136/heart.87.5.488.
    1. Pedersen SS, Theuns DA, Erdman RA, Jordaens L. Clustering of device-related concerns and type D personality predicts increased distress in ICD patients independent of shocks. Pacing Clin Electrophysiol. 2008;31:20–27. doi: 10.1111/j.1540-8159.2008.01158.x.
    1. Pedersen SS, van Domburg RT, Theuns DA, Jordaens L, Erdman RA. Concerns about the implantable cardioverter defibrillator: a determinant of anxiety and depressive symptoms independent of experienced shocks. Am Heart J. 2005;149:664–669. doi: 10.1016/j.ahj.2004.06.031.
    1. Broek KC Van den, Denollet J, Nyklicek I, Voort PH Van der. Psychological reaction to potential malfunctioning of implantable defibrillators. Pacing Clin Electrophysiol. 2006;29:953–956. doi: 10.1111/j.1540-8159.2006.00468.x.
    1. Sears SF, Lewis TS, Kuhl EA, Conti JB. Predictors of quality of life in patients with implantable cardioverter defibrillators. Psychosomatics. 2005;46:451–457. doi: 10.1176/appi.psy.46.5.451.
    1. Pedersen SS, van Domburg RT, Theuns DA, Jordaens L, Erdman RA. Type D personality is associated with increased anxiety and depressive symptoms in patients with an implantable cardioverter defibrillator and their partners. Psychosom Med. 2004;66:714–719. doi: 10.1097/01.psy.0000132874.52202.21.
    1. Whang W, Albert CM, Sears SF Jr, Lampert R, Conti JB, Wang PJ, Singh JP, Ruskin JN, Muller JE, Mittleman MA. TOVA Study Investigators. Depression as a predictor for appropriate shocks among patients with implantable cardioverter-defibrillators: results from the Triggers of Ventricular Arrhythmias (TOVA) study. J Am Coll Cardiol. 2005;45:1090–1095. doi: 10.1016/j.jacc.2004.12.053.
    1. Dunbar SB, Kimble LP, Jenkins LS, Hawthorne M, Dudley W, Slemmons M, Langberg JJ. Association of mood disturbance and arrhythmia events in patients after cardioverter defibrillator implantation. Depress Anxiety. 1999;9:163–168. doi: 10.1002/(SICI)1520-6394(1999)9:4<163::AID-DA3>;2-B.
    1. Lampert R, Joska T, Burg MM, Batsford WP, McPherson CA, Jain D. Emotional and physical precipitants of ventricular arrhythmia. Circulation. 2002;106:1800–1805. doi: 10.1161/01.CIR.0000031733.51374.C1.
    1. Weber CS, Thayer JF, Rudat M, Sharma AM, Perschel FH, Buchholz K, Deter HC. Salt-sensitive men show reduced heart rate variability, lower norepinephrine and enhanced cortisol during mental stress. J Hum Hypertens. 2008;22:423–431. doi: 10.1038/jhh.2008.11.
    1. Pedersen SS, Broek KC van den, Sears SF Jr. Psychological intervention following implantation of an implantable defibrillator: a review and future recommendations. Pacing Clin Electrophysiol. 2007;30:1546–1554.
    1. Sears SF, Sowell LD, Kuhl EA, Kovacs AH, Serber ER, Handberg E, Kneipp SM, Zineh I, Conti JB. The ICD shock and stress management program: a randomized trial of psychosocial treatment to optimize quality of life in ICD patients. Pacing Clin Electrophysiol. 2007;30:858–864. doi: 10.1111/j.1540-8159.2007.00773.x.
    1. Lewin RJ, Coulton S, Frizelle DJ, Kaye G, Cox H. A brief cognitive behavioural preimplantation and rehabilitation programme for patients receiving an implantable cardioverter-defibrillator improves physical health and reduces psychological morbidity and unplanned readmissions. Heart. 2009;95:63–69. doi: 10.1136/hrt.2007.129890.
    1. Kuhl EA, Sears SF, Vazques LD, Conti JB. Patient-assisted computerized education for recipients of implantable cardioverter defibrillators: a randomized controlled trial of the PACER program. J Cardiovasc Nurs. 2009;24:225–231.
    1. Pedersen SS, Denollet J. Is Type D personality here to stay? Emerging evidence across cardiovascular disease patient groups. Curr Cardiol Rev. 2006;2:205–213. doi: 10.2174/157340306778019441.
    1. Denollet J. DS14: standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom Med. 2005;67:89–97. doi: 10.1097/01.psy.0000149256.81953.49.
    1. Kuhl EA, Dixit NK, Walker RL, Conti JB, Sears SF. Measurement of patient fears about implantable cardioverter defibrillator shock: an initial evaluation of the Florida Shock Anxiety Scale. Pacing Clin Electrophysiol. 2006;29:614–618. doi: 10.1111/j.1540-8159.2006.00408.x.
    1. Rector TS, Kubo SH, Cohn JN. Patient's self-assessment of their congestive heart failure. Content, reliability, and validity of a new measure: the Minnesota Living with Heart Failure Questionnaire. Heart Failure. 1987;10:198–209.
    1. Burns JL, Serber ER, Keim S, Sears SF. Measuring patient acceptance of implantable cardiac device therapy: initial psychometric investigation of the Florida Patient Acceptance Survey. J Cardiovasc Electrophysiol. 2005;16:384–390.
    1. Pedersen SS, Spindler H, Johansen JB, Mortensen PT, Sears SF. Correlates of patient acceptance of the cardioverter defibrillator: cross-validation of the Florida Patient Acceptance Survey in Danish patients. Pacing Clin Electrophysiol. 2008;31:1168–1177. doi: 10.1111/j.1540-8159.2008.01158.x.
    1. Hellhammer J, Fries E, Schweisthal OW, Schlotz W, Stone AA, Hagemann D. Several daily measurements are necessary to reliably assess the cortisol rise after awakening: state- and trait components. Psychoneuroendocrinology. 2007;32:80–86. doi: 10.1016/j.psyneuen.2006.10.005.
    1. Kraemer HC, Giese-Davis J, Yutsis M, O'Hara R, Neri E, Gallagher-Thompson D, Taylor CB, Spiegel D. Design decisions to optimize reliability of daytime cortisol slopes in an older population. Am J Geriatr Psychiatry. 2006;14:325–333. doi: 10.1097/01.JGP.0000201816.26786.5b.
    1. Spek V, Cuijpers P, Nyklicek I, Riper H, Keyzer J, Pop V. Internet-based cognitive behaviour therapy for symptoms of depression and anxiety: a meta-analysis. Psychol Med. 2007;37:319–328. doi: 10.1017/S0033291706008944.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever